Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox
← Back to News

NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer

J

By João L. Carapinha

November 16, 2026

Clinical Practice
capsule sponge tests for oesophageal cancer

NICE has published draft guidance recommending capsule sponge tests for oesophageal cancer as an option for people with persistent acid reflux. The draft, published for consultation on Monday 16 November 2026, names two tests: Cytosponge, made by Medtronic, and EndoSign, made by Cyted Health.

The tests are aimed at people with persistent gastro-oesophageal reflux disease (GORD) who have multiple risk factors and do not need an urgent suspected cancer referral. They can be carried out in primary care and community diagnostic centres rather than in hospital, and need no sedation. Barrett’s oesophagus affects an estimated 1 to 2% of adults and raises the risk of oesophageal cancer, so earlier detection matters.

Capsule sponge tests for oesophageal cancer: how they work

A person swallows a capsule attached to a thread. The capsule dissolves, and the sponge inside expands in the stomach over about 7 minutes. A healthcare professional then pulls the sponge back up, collecting cells on the way. One trained healthcare professional can run the test, whereas an endoscopy needs at least 2 nurses and an endoscopist. Around 95 out of every 100 people swallow the capsule successfully after one or more attempts.

Why it matters

This is the first guidance under the National HealthTech Access Programme, which aims for consistent access to recommended technologies across England. Syenza News covered the programme’s announcement in February. If final guidance due in February 2027 confirms the recommendation, NHS England must begin delivering the test within the clinical pathway.

NICE’s committee believes the tests will reduce demand on NHS endoscopy services. Demand is high, and in some parts of the NHS people with Barrett’s oesophagus are not being checked as often as current guidance recommends. A negative result still needs advice on when to seek further help, because no test, endoscopy included, identifies every case. Comments close on 7 December 2026, and the committee meets on 16 December 2026 before final draft guidance in January 2027.

Source: NICE news release, 16 November 2026

Let Google know we are your trusted source.

Add our editorial as a preferred source in your search results.

Trust this Source

Value Science Weekly

The week in health technology assessment, market access and health economics — what moved, and what it means.

You can unsubscribe at any time. Read our privacy policy.

About this newsletter →